Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

A Nova radio host has admitted live on-air to taking a weight loss drug popular with celebrities that costs an arm and a leg ...

Novo Nordisk's blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year. The Danish pharmaceutical giant said sales of Wegovy ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Access to weight-loss jabs will now be more tightly regulated in the UK following concerns of pharmacies not prescribing them ...

The General Pharmaceutical Council (GPhC) has introduced new rules for weight-loss jabs, such as Wegovy and Mounjaro, in ...

Around half a million Britons are now thought to be using the medication, which can help them lose up to 20 per cent of their ...

LBC can reveal the Advertising Standards Authority issued a warning to a weight loss treatment provider over an advert which ...

In the short space of a year, it’s gone from a miracle drug reserved for the rich and famous to something everyday folk like ...